Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
darolutamide + radiotherapy
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral, External Beam Radiation
01
Overview
Darolutamide + radiotherapy is a combination therapeutic regimen being investigated for the treatment of oligometastatic castrate-resistant prostate cancer. The regimen consists of darolutamide (Nubeqa), a non-steroidal small molecule androgen receptor (AR) antagonist, and local consolidation radiotherapy, typically delivered as stereotactic ablative body radiotherapy (SABR). Darolutamide functions by competitively inhibiting androgen binding to the AR, inhibiting nuclear translocation of the AR, and blocking AR-mediated DNA transcription. This specific combination is the focus of the Phase 2 DECREASE trial (NCT04319783), sponsored by the Trans Tasman Radiation Oncology Group (TROG). The trial targets patients who are classified as non-metastatic (M0) by conventional imaging but are found to have limited metastatic disease (1-5 metastases, M1) via PSMA PET imaging, aiming to determine if adding metastasis-directed radiation to standard AR-targeted therapy improves progression-free and overall survival.
- Brand names
- Nubeqa
- Other names
- Darolutamide + RadiotherapyDarolutamide and Radiotherapy in PSMA-detected Advanced Prostate Cancer
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on darolutamide + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on darolutamide + radiotherapy.